Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) Patents (Class 424/139.1)
  • Patent number: 11160837
    Abstract: Provided are Megamonas funiformis and applications thereof. Specifically, the Megamonas funiformis has the effects for preventing and/or treating inflammation-related diseases, such as inflammatory bowel diseases (such as ulcerative enteritis, gastritis, and general enteritis) and cardiovascular diseases.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: November 2, 2021
    Assignee: BGI SHENZHEN
    Inventors: Yuanqiang Zou, Liang Xiao, Xiaoping Li, Jinghong Yu, Chuan Liu
  • Patent number: 11154616
    Abstract: The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventor: Daniel ShinYu Chen
  • Patent number: 11124556
    Abstract: The present invention relates to a library of particles, the library displaying a plurality of different T cell receptors (TCRs), wherein the plurality of TCRs consists essentially of TCRs comprising an alpha chain variable domain and a beta chain variable domain, wherein the alpha chain variable domain comprises a TRAV12-2 gene product and the beta chain variable domain comprises a TRBV gene product.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: September 21, 2021
    Assignees: Immunocore Limited, Adaptimmune Limited
    Inventors: Bent Karsten Jakobsen, Nathaniel Ross Liddy, Peter Eamon Molloy, Annelise Brigitte Vuidepot
  • Patent number: 11111271
    Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: September 7, 2021
    Assignee: COHBAR, INC.
    Inventors: Kenneth C. Cundy, Kent K. Grindstaff, Remi Magnan, Wendy Luo, Yongjin Yao, Liang Zeng Yan
  • Patent number: 11103551
    Abstract: The present invention is related to a method or a pharmaceutical composition for treatment or prevention of a cancer through blocking the interaction of ?4 integrin and focal adhesion kinase (FAK).
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: August 31, 2021
    Inventors: Tang-Long Shen, Yu-Ling Tai, Hsin-Jung Wu
  • Patent number: 11078272
    Abstract: Methods are provided for targeting pediatric brain tumor cells for depletion.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 3, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Sharareh Gholamin, Samuel Cheshier, Siddhartha S. Mitra, Irving L. Weissman
  • Patent number: 11078239
    Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: August 3, 2021
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Baoshan Zhang, Guillaume Stewart-Jones, Tongqing Zhou, John Mascola, Kai Xu, Yongping Yang, Paul Thomas, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
  • Patent number: 11072655
    Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: July 27, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ravindra Majeti, Irving L. Weissman, Siddhartha Jaiswal, Mark P. Chao
  • Patent number: 11059910
    Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 13, 2021
    Assignee: NovImmune SA
    Inventors: Krzysztof Masternak, Nicolas Fischer, Francois Rousseau, Elie Dheilly, Marie Kosco-Vilbois
  • Patent number: 11047651
    Abstract: An armor component that includes a ballistic tile made of, for example, boron carbide or silicon carbide, a plurality of wraps made of ballistic fibers such as carbon fiber, and a metal plate, for example, a steel plate, the metal plate being positioned behind the reverse side of the tile and the wraps being wrapped around the tile and the metal plate.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: June 29, 2021
    Assignee: VERCO MATERIALS, LLC
    Inventors: Robert F. Speyer, John Shupe
  • Patent number: 11046782
    Abstract: Isolated or recombinant monoclonal antibodies that bind to GARP are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. Further provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of an anti-platelet agent and a T cell therapy.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 29, 2021
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventor: Zihai Li
  • Patent number: 11033616
    Abstract: The present invention relates to exogenous feline paramyxovirus genes, which are expressed from recombinant viral vector systems.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: June 15, 2021
    Inventors: Hervé Poulet, Veljko Nikolin, Abraham Johannes De Smit, Teshome Mebatsion
  • Patent number: 11028172
    Abstract: Provided are anti-TIGIT antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the TIGIT protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: June 8, 2021
    Assignee: Lepu Biopharma Co., Ltd.
    Inventors: Wenci Gong, Yiwei Tou
  • Patent number: 11014990
    Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: May 25, 2021
    Assignee: ALS Therapy Development Institute
    Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
  • Patent number: 11013815
    Abstract: Human anti-human folate receptor beta (FR?) antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat a disorder, including but not limited to inflammatory disorders or cancers expressing cell surface FR?.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: May 25, 2021
    Assignee: Monojul, LLC
    Inventors: Cheryl Nickerson-Nutter, David Smolin
  • Patent number: 11007146
    Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: May 18, 2021
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Mauro Sergi, Peter Casteels
  • Patent number: 11001607
    Abstract: The peptide has from 3 to 10 amino acids comprising at least the sequence K*(Ac)GH or K*(Ac)HG and may further comprise an N-terminus modification, preferably an acylation, and/or a C-terminus modification; K* is selected from the group consisting of lysine, ornithine, diaminobutyric acid, diaminopropionic acid and a hydroxylated derivative thereof; K*(Ac) corresponds to a lysine, ornithine, diaminobutyric acid, diaminopropionic acid or a hydroxylated derivative thereof, acetylated on the amine of their lateral hydrocarbon chain. The two preferred peptides are Pal-K(Ac)GH and Pal-K(Ac)HG. This peptide can be used for a cosmetic treatment, in particular anti-aging, anti-wrinkle and fine lines, to improve the mechanical properties of the skin, firmness/tonicity/elasticity/flexibility, to increase the density and volume of the skin, for a restructuring, healing effect, and/or to fight stretch marks.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: May 11, 2021
    Assignee: Sederma
    Inventors: Olivier Peschard, Anne Doucet, Richard Leroux, Philippe Mondon
  • Patent number: 10989718
    Abstract: Methods and kits are provided for amplifying and detecting ?S proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded ?S protein may include: contacting the sample with a monomeric, folded ?S protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded ?S protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded ?S protein in the presence of the soluble, misfolded ?S protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded ?S aggregate present; and determining the presence of the soluble, misfolded ?S protein in the sample by detecting at least a portion of the soluble, misfolded ?S protein.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 27, 2021
    Assignees: Amprion, Inc., The Board of Regents of the University of Texas System
    Inventors: Claudio Soto Jara, Mohammad Shahnawaz, Russell M. Lebovitz, Benedikt K. Vollrath
  • Patent number: 10973867
    Abstract: Methods for treating retinopathy are provided and include administering an effective amount of a polypeptide antagovist of a Na/K ATPase/Src receptor complex to a subject. The retinopathy can include diabetic retinopathy. Methods of decreasing angiogenesis in a retinal vasculature are also provided and include the step of administering, such as by intravitreous injection, a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: April 13, 2021
    Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATION
    Inventors: Zijian Xie, Joseph I. Shapiro
  • Patent number: 10975134
    Abstract: The application relates to compositions or formulations comprising variant IL-10 molecules, fusion proteins, and chimeric proteins thereof useful for the treatment of cancer, inflammatory diseases or disorders, and autoimmune diseases or disorders.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 13, 2021
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • Patent number: 10955420
    Abstract: This document relates to materials and methods for identifying and monitoring immunoglobulin cleavage (e.g., IgG cleavage) in a sample, such as a biological sample, using mass spectrometry techniques.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: March 23, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: David R. Barnidge, David L. Murray
  • Patent number: 10919959
    Abstract: Angiopoietin-like protein (ANGPTL)3/8 complexes and antibodies are disclosed, where the antibodes bind to and thereby neutralize ANGPTL3/8 complexes. Pharmaceutical compositions also are disclosed that include one or more anti-ANGPTL3/8 complex antibodies herein in a pharmaceutically acceptable carrier. Methods of making and using the same also are disclosed, especially for increase lipoprotein lipase activity and lowering triglycerides. In this manner, the compounds and compositions may be used in treating lipid metabolism-related and glucose metabolism-related diseases and disorders.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 16, 2021
    Assignee: Eli Lilly and Company
    Inventors: Qing Chai, Jonathan Wesley Day, Robert John Konrad, Yuewei Qian, Oliver Schroeder, Robert William Siegel
  • Patent number: 10899838
    Abstract: The invention relates to an antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory T lymphocytes, and also to the use of this antibody for the treatment of diseases associated with the suppressor activity of regulatory T lymphocytes, in particular the treatment of cancer.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: January 26, 2021
    Assignees: Universite de Lille, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Cellvax, Universite Paris-Saclay
    Inventors: Nadira Delhem, Pierre Busson, Olivier Morales, Clement Barjon, Dhafer Mrizak, Claire Lhuillier, Rami Mustapha
  • Patent number: 10900086
    Abstract: The present invention relates to compositions and methods and for the diagnosis, prognosis, and treatment of prostate cancer. The invention is based upon the identification of a gene expression signature that predicts the likelihood that prostate cancer will metastasize. Provided is a method of determining whether prostate cancer in a subject will metastasize. Also provided are compositions comprising a prostate cancer-associated gene. Also provided are kits comprising a package with a prostate cancer-associated gene.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 26, 2021
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Michaela Bowden, Svitlana Tyekucheva, Massimo Loda, Lorelei Mucci
  • Patent number: 10881734
    Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: January 5, 2021
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Chigusa Yoshimura, Reimi Kawaida, Kokichi Honda
  • Patent number: 10882922
    Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 5, 2021
    Assignee: SANOFI
    Inventors: Zhi-Yong Yang, Gary J. Nabel, Lan Wu, Edward Seung, Ronnie Wei, Jochen Beninga, Ercole Rao, Wulf Dirk Leuschner, Christian Beil, Christian Lange, Carsten Corvey
  • Patent number: 10869926
    Abstract: Impressive responses have been observed in patients treated with checkpoint inhibitory anti-PD-1 or anti-CTLA-4 antibodies. However, immunotherapy against poorly immunogenic cancers remains a challenge. Treatment with both anti-PD-1 and anti-CTLA-4 antibodies were unable to eradicate large, modestly immunogenic CT26 tumors or metastatic 4T1 tumors. However, co-treatment with epigenetic modulating drugs and checkpoint inhibitors markedly improved treatment outcomes, curing more than 80% of them. Functional studies revealed that the primary targets of the epigenetic modulators were myeloid-derived suppressor cells (MDSCs). A PI3K-inhibitor that reduced circulating MDSCs also cured 80% of mice with metastatic 4T1 tumors when combined with immune checkpoint inhibitors. Thus, cancers resistant to immune checkpoint blockade can be cured by eliminating MDSCs.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: December 22, 2020
    Assignee: The Johns Hopkins University
    Inventors: Shibin Zhou, Bert Vogelstein, Kenneth W. Kinzler, KiBem Kim
  • Patent number: 10858421
    Abstract: The present invention relates to inhibitors of C5a for use in the treatment of pneumonia, especially viral pneumonia. The invention also relates to the use of inhibitors of C5a in the preparation of a pharmaceutical composition for the treatment of pneumonia, especially viral pneumonia. The inventors further relates to methods for the treatment of pneumonia, especially viral pneumonia, comprising the step of administering a therapeutic amount of an inhibitor of C5a to a subject in need thereof.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: December 8, 2020
    Assignee: INFLARX GMBH
    Inventors: Renfeng Guo, Niels Christoph Riedemann
  • Patent number: 10844127
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 24, 2020
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers
  • Patent number: 10835593
    Abstract: Disclosed is a Bacillus anthracis protective antigen (PA) comprising a PA amino acid sequence, wherein one or more of amino acid residues I207, I210, E654, I656, R659, M662, Y681, and L687, as defined by reference to SEQ ID NO: 1, are, independently, substituted, with the proviso that amino acid residue I207 is not substituted with alanine and amino acid residue I210 is not substituted with alanine. Related compositions, nucleic acids, recombinant expression vectors, host cells, populations of cells, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 17, 2020
    Assignee: The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Shi-Hui Liu, Stephen H. Leppla, Thomas H. Bugge, Alexander N. Wein, Diane E. Peters, Jie Liu, Kuang-Hua Chen
  • Patent number: 10836830
    Abstract: The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
    Type: Grant
    Filed: June 19, 2020
    Date of Patent: November 17, 2020
    Assignees: AGENUS INC., MEMORIAL SLOAN-KETTERING CANCER CENTER, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
  • Patent number: 10815534
    Abstract: This document provides methods and materials for treating cancer (e.g., estrogen receptor positive breast cancer). For example, methods and materials for identifying a mammal (e.g., a human) with cancer (e.g., estrogen receptor positive breast cancer) as having A?G variant genotype of rs6990851 and/or as having an elevated level of CSMD1 nucleic acid expression and administering one or more aromatase inhibitors (e.g., anastrozole) to treat the mammal identified as having such genotype and/or elevated level are provided.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 27, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Tanda T. Dudenkov, Liewei Wang, James N. Ingle, Richard M. Weinshilboum, Junmei Cairns
  • Patent number: 10808029
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: October 20, 2020
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-wa Chung, Susannah Karen Ford, Ian Kirby, Ruth McAdam, Maria Feeney
  • Patent number: 10806771
    Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: October 20, 2020
    Assignee: BIOINCEPT, LLC
    Inventor: Eytan R. Barnea
  • Patent number: 10774119
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: September 15, 2020
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Marlon Hinner, Alexander Wiedenmann, Andrea Allersdorfer
  • Patent number: 10766959
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: September 8, 2020
    Assignee: Pierre Fabre Medicament
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen
  • Patent number: 10724014
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: July 28, 2020
    Assignees: Institut National de la Sante et de la Recherche Medicale, Université Paul Sabatier Toulouse III
    Inventor: Elvire Gouze
  • Patent number: 10722578
    Abstract: Methods and compositions for treating neuroblastoma are disclosed.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: July 28, 2020
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Yael P. Mosse, Erica L. Carpenter
  • Patent number: 10717778
    Abstract: The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: July 21, 2020
    Assignees: DUKE UNIVERSITY, MACROGENICS, INC., THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Barton F. Haynes, Guido Ferrari, Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Julia A. Sung, David M. Margolis, Liqin Liu, Jeffrey Lee Nordstrom
  • Patent number: 10646567
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: May 12, 2020
    Assignee: Genentech, Inc.
    Inventors: Heather Maecker, Bryan Irving
  • Patent number: 10640564
    Abstract: The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: May 5, 2020
    Assignee: Ichnos Sciences SA
    Inventors: Rami Lissilaa, Adrian Walmsley, Stanislas Blein, Romain Ollier, Samuel Hou, Jeremy Loyau
  • Patent number: 10640777
    Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: May 5, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PANGEN BIOTECH INC.
    Inventors: Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee
  • Patent number: 10639368
    Abstract: The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 5, 2020
    Assignee: AGENUS INC.
    Inventors: Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
  • Patent number: 10626170
    Abstract: Provided are antibodies that bind to: a sulfonated epitope of the protein Sclerostin, to Sclerostin portions comprising a sulfonated amino acid and to dimerized forms of Sclerostin. Further provided are compositions and peptides comprising a sulfonated epitope of sclerostin. Also provided by this invention are methods for production of such antibodies, both active and passive, and methods for identifying antibodies specific for sulfonation sites in Sclerostin and other antibodies which discriminate between sulfonated and unsulfonated forms of sclerostin. Physical and virtual screening processes are provided in this invention for identifying compounds which disrupt or inhibit sulfonation and the interaction between Sclerostin and binding partners. The antibodies and compositions of the present invention are useful in diagnostic and therapeutic applications directed to Sclerostin-related disorders.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 21, 2020
    Assignee: Enzo Biochem, Inc.
    Inventor: Joshua Rabbani
  • Patent number: 10611850
    Abstract: Described herein are anti-PCSK9 antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: April 7, 2020
    Assignee: Amgen Inc.
    Inventors: Twinkle R. Christian, Christi L. Clogston, Timothy David Osslund
  • Patent number: 10611846
    Abstract: The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: April 7, 2020
    Assignee: ZymoGenetics, Inc.
    Inventor: Janine M. Bilsborough
  • Patent number: 10610592
    Abstract: A composition for treating neurodegeneration, including an antibiotic, an antifungal agent, and a lipophilic potentiating agent in synergistically effective amounts. A method of treating neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and treating neurodegeneration. A method of reducing and/or eliminating symptoms of neurodegeneration, by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration, and reducing and/or eliminating the individual's symptoms of neurodegeneration. A method of reducing and/or eliminating lesions from neurodegeneration. A method of recovering mobility of an individual suffering from neurodegeneration.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: April 7, 2020
    Inventor: Fabrizio De Silvestri
  • Patent number: 10604571
    Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 31, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PANGEN BIOTECH INC.
    Inventors: Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee
  • Patent number: 10604572
    Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 31, 2020
    Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PANGEN BIOTECH INC.
    Inventors: Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee
  • Patent number: 10570204
    Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: February 25, 2020
    Assignees: The Medical College of Wisconsin, Inc., Novartis AG
    Inventors: Bryon Duane Johnson, Robert Millman